Yevhen Hotko
Yevhen Hotko
Professor of Medicine (Oncology), Uzhhorod National University. Oncologist, Central City Hospital.
Підтверджена електронна адреса в uzhnu.edu.ua - Домашня сторінка
Назва
Посилання
Посилання
Рік
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ...
New England Journal of Medicine 359 (17), 1757-1765, 2008
38432008
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
R Pirker, JR Pereira, A Szczesna, J Von Pawel, M Krzakowski, R Ramlau, ...
The Lancet 373 (9674), 1525-1531, 2009
16522009
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
GU 31. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R ...
Lancet 373 (9674), 1525-31, 2009
16522009
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with …
M Peeters, T Jay Price
JOURNAL OF CLINICAL ONCOLOGY, 2010
10262010
RANDOMIZED PHASE III STUDY OF PANITUMUMAB WITH FLUOROURACIL, LEUCOVORIN, AND IRINOTECAN (FOLFIRI) COMPARED WITH FOLFIRI ALONE AS SECOND-LINE TREATMENT IN PATIENTS WITH …
GJ 32. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y ...
J Clin Oncol 28 (31), 4706-13, 2010
10262010
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
HY Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U ...
The New England Journal of Medicine 378 (26), 2465-2474, 2018
4382018
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
BMW 29. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B ...
Lancet Oncol 10 (2), 135-46, 2009
3542009
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C …
A Testori, J Richards, E Whitman, GB Mann, J Lutzky, L Camacho, ...
Clinical Oncology, 2006
2422006
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
PR O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM ...
Lancet Oncol 12 (8), 795-805, 2011
2132011
Final results from a randomized phase 3 study of FOLFIRI±panitumumab for second-line treatment of metastatic colorectal cancer
M Peeters, TJ Price, A Cervantes, AF Sobrero, M Ducreux, Y Hotko, ...
Annals of Oncology 25 (1), 107-116, 2014
1672014
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Clin. Cancer Res. 21 (24), 5469-79, 2015
1372015
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with …
SJW 25. O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A ...
J Thorac Oncol 3 (7), 728-34, 2008
1352008
Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with …
SJW O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky ...
Journal of Thoracic Oncology 3 (7), 728-34, 2008
1352008
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
KJ O'byrne, I Bondarenko, C Barrios, C Eschbach, U Martens, Y Hotko, ...
Journal of Clinical Oncology 27 (15_suppl), 8007-8007, 2009
1252009
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
ERJ 36. Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska ...
Ann Oncol 23 (3), 610-617, 2012
952012
14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
M Peeters, T Price, Y Hotko, A Cervantes, M Ducreux, T André, E Chan, ...
EJC Supplements 3 (7), 10, 2009
692009
Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic …
M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ...
Journal of Clinical Oncology 32 (3_suppl), LBA387-LBA387, 2014
552014
Panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer
et al Peeters M, Wilson G, Hotko Y, Ducreux M, Cervantes A, André T
Alimentary Pharmacology and Therapeutics 28 (3), 269-281, 2008
552008
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy …
YLW Saulius Cicènas, Sarayut Lucien Geater, Petar Petrovc, Yevhen Hotko ...
Lung Cancer 102, Pages 30–37, 2016
422016
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic …
M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ...
Journal of Clinical Oncology 32 (15_suppl), 3568-3568, 2014
382014
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20